| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q3 2018 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTRA-CELLULAR THERAPIES INC | 16 | Q3 2023 | 10.2% |
| MICRON TECHNOLOGY INC | 16 | Q3 2023 | 6.7% |
| ALPHABET INC | 16 | Q3 2023 | 5.8% |
| ABBVIE INC | 16 | Q3 2023 | 7.9% |
| REGENERON PHARMACEUTICALS | 16 | Q3 2023 | 5.5% |
| ARGENX SE | 16 | Q3 2023 | 6.4% |
| SPDR GOLD TRUST | 16 | Q3 2023 | 6.6% |
| XENCOR INC | 16 | Q3 2023 | 4.1% |
| BK OF AMERICA CORP | 16 | Q3 2023 | 5.4% |
| ORACLE CORP | 16 | Q3 2023 | 3.2% |
View DCF Advisers, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-09 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-11 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-10 |
| 13F-HR | 2021-11-15 |
View DCF Advisers, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.